Previous 10 | Next 10 |
2024-05-24 14:26:46 ET More on HOOKIPA Pharma Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts Hookipa to receive $10M from Roche as FDA clears cancer trial Seeking Alpha’s Quant Rating on HOOKIPA Pharma Historical earn...
2024-05-24 12:58:09 ET More on BioAtla, HOOKIPA Pharma, etc. BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript AEye, Inc. (LIDR) Q1 2024 Earnings Call Transcript BioAtla: A Buried ADC Concern Gets Some New Life In 2024 AEye Q1 2024 Earnings Preview ...
HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4 Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile and promising clinical activity In a subset of patients with PD-L1 combined posit...
2024-05-16 14:27:26 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks to buy understandably offer many enticing attributes, not least of which is the potential for tremendous returns. Of course, the emphasis is on the word “potential. ...
2024-05-09 11:55:05 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips HOOKIPA Pharma (NASDAQ: HOOK ) just reported results for the first quarter of 2024. HOOKIPA Pharma reported earnings per share of 11 cents. This was above the analyst esti...
2024-05-09 07:57:23 ET More on HOOKIPA Pharma Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts Hookipa to receive $10M from Roche as FDA clears cancer trial Seeking Alpha’s Quant Rating on HOOKIPA Pharma Historical earn...
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligns with U.S. Food and Drug Administration (FDA) feedback HB-200 program received Priority Medicines (PRIME) de...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from...
2024-04-24 14:01:40 ET More on HOOKIPA Pharma Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts Hookipa to cut 30% of workforce in wake of Roche deal termination Seeking Alpha’s Quant Rating on HOOKIPA Pharma Historical ...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...
2024-07-09 09:02:05 ET Hookipa Pharma Inc (HOOK) announced stock split at a ratio of 1-for-10 on 2024-07-10 ... Full story available on KlickAnalytics.com